Roy Papatheodorou has been named as EVP, General Counsel and Head of Legal, Ethics & Business Integrity; taking over from Karen Linehan who is retiring after 14 years at Sanofi. Papatheodorou will Sanofi from Novartis, where he is the General Counsel of Novartis Pharmaceuticals. In the past, he has headed the Legal Transactions team at Novartis and having previously been the General Counsel of the Actavis Group, one of the largest generic companies at the time. He started his career at international law firm Linklaters, where he specialized in international M&A, corporate, and private equity.
Brendan O’Callaghan has been appointed EVP, Global Head of Industrial Affairs; taking over from Philippe Luscan who retires after 13 years in the role and 32 years with the company. O’Callaghan is currently Sanofi’s Global Head of its Biologics Platform and the Industrial Affairs head of its Specialty Care portfolio. He joined Sanofi in 2015 from Merck where he had served as Head of Biologics and later Vice President of their EMEA Operations.
Additionally, Viviane Monges will join EUROAPI, a European company dedicated to the development, production, and marketing of active pharmaceutical ingredients (API), as an independent non-executive Chair of the Supervisory Board. She will serve as Chair of the Board of Directors upon transformation of EUROAPI into a société anonyme, in compliance with applicable corporate governance regulations.
Monges’ career has spanned several industries: she was CFO of the Business Excellence Division at Nestlé; served as Group CFO at Galderma S.A.; and was EMEA CFO and then Global CFO of the OTC Division at Novartis. At Wyeth Pharmaceuticals/Pfizer she served as CFO of the Global Pharma Business unit. She also worked for Agence France-Presse from 1990 to 1995.
She is currently an independent Director at several pharmaceutical companies: UCB, Novo Holdings, DBV Technologies, ADC Therapeutics, and Pharvaris. She also served on the Board of Idorsia from 2018 to 2021.